Diagnostics for resource-limited settings in the era of interferon-free HCV therapy

Summary The field of hepatitis C (HCV) therapy is moving inexorably towards a time when interferon is no longer part of routine HCV treatment. 2015 will see at least two interferon‐free directly acting antiviral (DAA) treatments licensed in Europe and the USA. For those parts of the world that can a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2015-05, Vol.22 (5), p.459-460
Main Authors: Cooke, G. S., Hill, A. M.
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Developing Countries
Diagnostic Tests, Routine - methods
diagnostics
Europe
HCV
Hepatitis C - diagnosis
Hepatitis C - drug therapy
HIV/HCV
Humans
Interferon
Point-of-Care Systems
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The field of hepatitis C (HCV) therapy is moving inexorably towards a time when interferon is no longer part of routine HCV treatment. 2015 will see at least two interferon‐free directly acting antiviral (DAA) treatments licensed in Europe and the USA. For those parts of the world that can afford it, this will mean the potential for treatment of those who have either failed interferon‐based therapy or have been unable to tolerate the side‐effects that commonly accompany treatment.
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.12401